Sandbox Reserved 1474: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 157: | Line 157: | ||
====Pharmacokinetics studies in rats==== | ====Pharmacokinetics studies in rats==== | ||
METH had little effect on ch-mAb7F9 disposition, ch-mAb7F9 substantially altered METH disposition. Both in vitro and in vivo demonstrated ch-mAb7F9 is pharmacologically similar to its murine counter part<ref name="Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use" /> | METH had little effect on ch-mAb7F9 disposition, ch-mAb7F9 substantially altered METH disposition. Both in vitro and in vivo demonstrated ch-mAb7F9 is pharmacologically similar to its murine counter part<ref name="Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use" />. Ch-mAb decreased the METH Vd by 5 and 25 fold at the 15 and 150mg/kg doses. Although METH t1/2lamdaz is increased 2 to 5 folds due to the decreased ClT to a greater degree, METH elimination was still rapid compared to ch-mAb elimination. (2-7 hrs v.s 10-13 d). | ||
In the current studies, a t1/2lamdaZ of 10-13 days for ch-mAb7F9 in rats was observed. The half life is predicted to be 3 weeks in human roughly 3 folds of that of rat due to the Vdss of IgG in both species is similar yet the | In the current studies, a t1/2lamdaZ of 10-13 days for ch-mAb7F9 in rats was observed. The half life is predicted to be 3 weeks in human roughly 3 folds of that of rat due to the volume of distribution at steady state (Vdss) of IgG in both species is similar yet the clearance time (Clt) in humans is one third of that in rats. | ||
